Effect of L-Carnitine Supplementation in Preterm Neonates
Effect of L-Carnitine Supplementation in Preterm Neonates Suffering From Respiratory Distress Syndrome (RDS)
Muhammad Aamir Latif
160 participants
Jan 1, 2026
INTERVENTIONAL
Summary
The current study is planned to see the effect of L-carnitine supplementation in preterm neonates suffering from RDS among the local population, as there is no such evidence available for the local population and there are conflicting statistics regarding the discharge rate of these neonates.
Eligibility
Inclusion Criteria4
- Preterm neonates
- Either gender
- With RDS
- Admitted to the neonatal intensive care unit (NICU) within 24 hours of birth .
Exclusion Criteria3
- Neonates with gastrointestinal tract (GIT) anomalies
- With confirmed or suspected sepsis at the time of enrollment
- Neonates whose clinical condition contraindicates study participation (e.g., expected survival <48 hours, as judged by the neonatologist).
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will receive L-carnitine at a therapeutic dosage of 30 mg/kg/day, in conjunction with a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Patients will get a standard care regimen comprising a total dosage of 100 mg phospholipids/kg birth weight (4 ml/kg), divided into four quarter-dose aliquots.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07437391